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A B S T R A C T
Background
The proteases (secretases) that cleave amyloid-b (Ab) peptide from the amyloid precursor
protein (APP) have been the focus of considerable investigation in the development of
treatments for Alzheimer disease. The prediction has been that reducing Ab production in the
brain, even after the onset of clinical symptoms and the development of associated pathology,
will facilitate the repair of damaged tissue and removal of amyloid lesions. However, no long-
term studies using animal models of amyloid pathology have yet been performed to test this
hypothesis.
Methods and Findings
We have generated a transgenic mouse model that genetically mimics the arrest of Ab
production expected from treatment with secretase inhibitors. These mice overexpress mutant
APP from a vector that can be regulated by doxycycline. Under normal conditions, high-level
expression of APP quickly induces fulminant amyloid pathology. We show that doxycycline
administration inhibits transgenic APP expression by greater than 95% and reduces Ab
production to levels found in nontransgenic mice. Suppression of transgenic Ab synthesis in
this model abruptly halts the progression of amyloid pathology. However, formation and
disaggregation of amyloid deposits appear to be in disequilibrium as the plaques require far
longer to disperse than to assemble. Mice in which APP synthesis was suppressed for as long as
6 mo after the formation of Ab deposits retain a considerable amyloid load, with little sign of
active clearance.
Conclusion
This study demonstrates that amyloid lesions in transgenic mice are highly stable structures
in vivo that are slow to disaggregate. Our findings suggest that arresting Ab production in
patients with Alzheimer disease should halt the progression of pathology, but that early
treatment may be imperative, as it appears that amyloid deposits, once formed, will require
additional intervention to clear.
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Introduction
Over a decade ago the amyloid cascade hypothesis
predicted that increased levels of amyloid-b (Ab) peptide
lead to secondary pathologies that ultimately culminate in
the onset of Alzheimer disease (AD) [1]. Early support for
this hypothesis came from genetic studies linking early-onset
AD to mutations in the amyloid precursor protein (APP),
from which Ab is derived, and presenilins 1 and 2, which are
interchangeable components of a endoprotease complex
that releases Ab from APP (for review see [2,3]). If, as
predicted, overproduction of Ab initiates the cascade of
events leading to disease, then therapeutic strategies that
lower Ab levels should either arrest or reverse the
progression from peptide to dementia.
Early evidence from clinical trials of antibody-mediated
clearance, one of the first Ab-lowering approaches tested in
humans, suggested that treatments designed to reduce
amyloid burden may indeed be beneficial. Although the
trials were halted because of adverse effects in a subset of
volunteers [4,5], further analysis of several patients found
evidence that amyloid pathology, and to a lesser degree
cognitive function, was improved in proportion to the
patient’s titer of Ab-specific antibody [6,7]. While this
approach is promising, constant exposure to antibodies
that recognize an epitope highly enriched in the brain may
have unexpected side effects that will limit its long-term use.
An alternative approach that is being actively pursued for
future treatment of AD seeks to lower Ab levels by limiting
its production from the precursor protein APP. Peptide Ab
is released from APP by the action of two enzymes, the b-
APP cleaving enzyme 1 (BACE1) and c-secretase, which
cleave the holoprotein at the N- and C-termini of Ab,
respectively. Several inhibitors of c-secretase have already
been produced [8,9], and small molecule inhibitors of b-APP
cleaving enzyme 1 are currently being developed [10,11].
The long-term effectiveness of this approach in either
humans or model systems, however, has not been reported.
Although loss of b-APP cleaving enzyme 1 function can
prevent the development of plaques in transgenic mouse
models for AD (F. Laird, H. Cai, P. C. Wong, personal
communication), it is not known whether the brain can clear
pre-existing amyloid deposits once production of Ab has
been suppressed.
Clearly, the amyloid-lowering approach should be rigor-
ously examined in animal models before these reagents are
tested in patients. However, the chemical secretase inhib-
itors most likely to reach human trials are still in develop-
ment. Therefore, we developed a mouse model of
Alzheimer-type amyloid that expresses a controllable APP
transgene. This system, commonly known as the tet-off
system, can be regulated by analogs of tetracycline admin-
istered in food or water [12,13]. The strong expression levels
produced with the tet-off vectors, combined with the ability
to reduce this expression by several orders of magnitude
with tetracycline [14], allowed for a stringent test of how a
highly effective pharmaceutical inhibitor of Ab production
would impact the progression of amyloid pathology and
whether reversal of these lesions might be possible following
such treatment.
Methods
Transgene Construction
We created a tetracycline-responsive chimeric mouse/
human APP695Swedish/Indiana (swe/ind) vector by replacing
the promoter region of the moPrP.XhoI vector (also known as
pPrPpE1/E2,3sal [15]) with the tetracycline-responsive pro-
moter of pTetSplice (Life Technologies, Rockville, Maryland,
United States), and then ligating mouse APP with a
humanized Ab domain (mo/huAPP695) cDNA into the new
vector. We began by cloning the tetracycline-responsive
promoter (bp 6–481) from pTetSplice by PCR using primers
that added external BamHI and NotI sites to the 59 end and a
BamHI site to the 39 end, while destroying XhoI and BamHI
sites within the promoter (forward: GCC GGA TCC GCG
GCC GCC GTC GAG TTT ACC ACT CCC TAT C; reverse:
GCC GGA TCC ACT CTA GAA GAT CCC CGG GTA CCG).
We then isolated the moPrP.XhoI intron by amplification
with primers that added an external BamHI site to the 59 end
of exon 1 and ran through the Asp718 site of exon 2 (forward:
GCC GGA TCC GAT CAG CAG ACC GAT TCT GG; reverse:
GCC GGT ACC ACT AGG AAG GCA GAA TGC). This 2-kb
intron fragment was cloned into a TA cloning vector
(Invitrogen, Carlsbad, California, United States), then excised
by Asp718 digestion and ligated to the 6.8-kb Asp718
fragment of moPrP.XhoI containing exon 2, exon 3, the 39
UTR, and pBluescript to generate an intermediate vector
with all three exons and a central intron but no promoter.
This vector was then opened at the BamHI site introduced by
the intron cloning primer, and ligated to the 0.5-kb BamHI-
cut tetracycline promoter fragment. This ligation generated a
9.3-kb vector encoding the tetracycline promoter from
pTetSplice with two exons, one intron, and the original 39
UTR of the moPrP.XhoI vector, all carried in the pBluescript
cloning vector.
We incorporated the Swedish (KM570/571NL) and Indiana
(V617F) mutations into the mo/huAPP695 cDNA (in BS-KS)
by PCR using a four-primer strategy: first, two partially
overlapping products were generated in separate reactions
using primers that encode the desired mutations (Swedish
forward: GGA GAT CTC TGA AGT GAA TCT GGA TGC
AGA ATT CCG/Indiana reverse: GGG TGA TGA AAA TCA
CGG TTG C; Indiana forward: CAA CCG TGA TTT TCA TCA
CCC TGG/M13 reverse). The two PCR products were ligated,
digested with BglII and ApaI and cloned back into the
original mo/huAPP695-BS-KS vector. Finally, the new
APP695swe/ind was subcloned into the XhoI site of the
moPrP-tetP vector from above to complete the construct.
Pronuclear Injection, Screening of Founders, and
Maintenance of the Lines
The moPrP-tetP-mo/huAPP695swe/ind vector was linear-
ized and the pBluescript domain excised by digestion with
NotI. The purified vector was injected into the pronucleus of
fertilized eggs from C57BL/6J 3 C3HeJ F1 matings. Founder
animals were screened for the presence of the transgene by
three-way PCR using the S36 and PrP-S/PrP-AS primers
described below. Transgene-positive founders were bred to
animals expressing the tetracycline transactivator (tTA)
under control of the calcium-calmodulin kinase IIa
(CaMKIIa) promoter obtained from Jackson Laboratory [16]
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(Bar Harbor, Maine, United States; stock # 3010; B6;CBA-
TgN[Camk2a-tTA]1Mmay). The colony was thereafter main-
tained by crossing single transgenic tTA and APP offspring
for each of the four APP lines. All mice were provided fresh
food and water ad libitum. Animal protocols were approved
by both the Johns Hopkins University and the California
Institute of Technology Institutional Animal Care and Use
Committees.
Doxycycline Administration
Doxycycline (dox) was administered through commercially
available dox-containing chow (BioServ, Frenchtown, New
Jersey, United States). The chow contained 200 mg/kg of
antibiotic; based on estimated consumption of 5 g per mouse
per day, the expected dose to each animal was 1 mg dox per
day. The average 25-g animal therefore received 40 lg of dox
per gram body weight per day. Chow was changed 1–2 times
per week to prevent breakdown of the antibiotic.
Genotyping
Offspring were genotyped for the presence of each trans-
gene by PCR amplification of genomic DNA extracted from a
5-mm tail biopsy. Tails were heated to 95 8C for 45 min in 250
ll of 50 mM NaOH, vortexed, then neutralized with an equal
volume of 0.5 M Tris-HCl (pH 5.5). Debris was sedimented by
centrifugation, and 3 ll of supernatant was used for
amplification.
Genotyping for APP and tTA transgenes was performed in
the same PCR reaction, using five separate primers. APP was
amplified using forward primer S36 located in the 39 end of
the APP cDNA (CCG AGA TCT CTG AAG TGA AGA TGG
ATG) and reverse primer PrP-AS-J located in the 39 UTR of
the vector (CCA AGC CTA GAC CAC GAG AAT GC). The
tTA transgene was detected using a primer set that amplified
across its two subdomains with tet forward located within the
Tn10 tetracycline repressor (CGC TGT GGG GCA TTT TAC
TTT AG) and tet reverse within the HSV1 VP16 (CAT GTC
CAG ATC GAA ATC GTC). All reactions, whether transgene-
positive or not, amplified a segment of the endogenous prion
protein gene as a control for DNA quality using a forward
primer, PrP-S-J, specific to the mouse PrP open reading
frame (GGG ACT ATG TGG ACT GAT GTC GG) and a
reverse primer, PrP-AS-J, shared by the 39 UTR of the
endogenous PrP gene and the transgene vector. Amplifica-
tion reactions were run for 37 cycles at 94 8C for 30 s, 64 8C
for 1 min, and 72 8C for 1 min. All samples, transgenic and
wild-type, gave a 750-bp product from the endogenous PrP
gene. The APP transgene yielded an additional band at 400
bp; the tTA product fell in between at 480 bp.
Immunoblotting/Quantitation
Frozen cortical or whole forebrain tissue was homogenized
by sonication in five volumes of phosphate-buffered saline
(PBS) with 5 mM EDTA and protease inhibitors (Mammalian
cell cocktail, Sigma, St. Louis, Missouri, United States), using a
probe sonicator set to 50% output (TEKMAR, Cincinnati,
Ohio, United States). After dilution with an equal volume of
PBS/EDTA/protease inhibitor, the samples were centrifuged
briefly and the supernatant used for analysis. Fifty micro-
grams (6E10 and CT15) or 5 lg (22C11) of brain homogenate
was loaded per lane onto 7.5%, 10%–20%, or 4%–20% Tris-
HCl PAGE gels (Bio-Rad Laboratories, Hercules, California,
United States) and electrophoresed for several hours in 13
Tris-glycine–sodium dodecyl sulfate (13TG-SDS) buffer (6E10
and 22C11; Amresco, Solon, Ohio, United States) or 13 Tris-
tricine-SDS buffer (CT15; Invitrogen, Carlsbad, California,
United States). Proteins were transferred overnight to 0.45-
lm Optitran nitrocellulose (Schleicher and Schuell, Keene,
New Hampshire, United States) in 13 TG buffer (Amresco).
Blots were blocked in PBS containing 5% nonfat dry milk
powder, and incubated for 3 h at room temperature in
blocking solution with one of the following antibodies: mouse
monoclonal 22C11 (kind gift of Konrad Beyreuther and
Andreas Weidemann; [17]) diluted 1:1,000, mouse monoclonal
6E10 (Signet Laboratories, Dedham, Massachusetts, United
States) diluted 1:2,500, rabbit polyclonal anti-superoxide
dismutase 1 (m/hSOD1) [18] diluted 1:2,500 to 1:4,000, or
rabbit polyclonal CT15 (kind gift of Ed Koo; [19]) diluted
1:1,000. Subsequently, the blots were washed with PBS
containing 0.1% Tween-20, and then incubated with either
goat anti-mouse– or goat anti-rabbit–HRP conjugated sec-
ondary antibody diluted 1:1,000 in blocking solution. After
several additional rinses in PBS with 0.1% Tween-20, blots
were developed with enhanced chemiluminescence reagent
and imaged with the Bio-Rad Molecular Imager FX system.
Staining intensity within each lane was quantified using the
Quantity One image analysis software (Molecular Imager FX,
Bio-Rad Laboratories). Background was calculated from
across the image and subtracted from the entire file. The
signal intensity for each band (corrected signal intensity 3
pixel number) was then calculated using the Volume report
tool.
Slot Blot mRNA Analysis
Five micrograms per sample of total RNA extracted from
fresh-frozen brain, liver, kidney, heart, lung, spleen, and
skeletal muscle was vacuum-filtered through 0.45-lm Opti-
tran nitrocellulose. After several washes through the manifold
with 103 SSC, blots were UV-cross-linked and probed with a
radiolabeled ;350-bp BglII–XhoI cDNA fragment of mo/
huAPP695 cDNA. After hybridizing overnight at 65 8C in 1%
BSA/1 mM EDTA/0.5 M sodium phosphate buffer (pH 7.2)/7%
SDS [20], the blots were washed twice at 65 8C for 30 min each
in 0.1% BSA/1 mM EDTA/40 mM sodium phosphate buffer
(pH 7.2)/5% SDS before two final 30-min washes at 65 8C with
1 mM EDTA/40 mM sodium phosphate buffer (pH 7.2)/1%
SDS. Blots were wrapped wet and exposed to phos-
phorscreens overnight at room temperature.
Amyloid Histology
Mice were euthanized by ether inhalation and brains
removed for immersion fixation in 4% paraformaldehyde/
13 PBS. After 48 h in fixative at 4 8C, brains were transferred
to PBS, dehydrated in alcohols, treated with cedarwood oil
and methylsalicylate, and embedded in paraffin for section-
ing.
Hirano silver stain. Silver impregnation histology was
performed on 10-lm paraffin-embedded sections by Hirano’s
modification of the Bielschowsky method [21]. Briefly,
sections were deparaffinized through xylene and alcohols
into tap water before being placed into fresh 20% silver
nitrate solution for 20 min. After being washed thoroughly
with distilled water, slides were immersed in 20% silver
nitrate solution titrated with fresh ammonium hydroxide.
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After 20 min, slides were washed with ammonia water before
being individually developed with 100 ll of developer (20 ml
of 37% formaldehyde, 100 ml of distilled water, 50 ll of
concentrated nitric acid, and 0.5 g of citric acid) added to 50
ml of titrated silver nitrate solution. Slides were then rinsed
in tap water, fixed in 5% sodium thiosulfate, and dehydrated
through alcohols and xylene.
Thioflavin-S staining. Following deparaffinization of sec-
tions through xylene and alcohols, amyloid impregnation
with thioflavin-S was performed according to the Guntern
modification of the standard protocol. Slides holding 10-lm
paraffin sections were washed twice in distilled water, then
immersed for 5 min in a 0.25% potassium permanganate
solution, followed by 5 min in a 1% potassium metabisulfate/
1% oxalic acid solution. After this preparation, slides were
placed into a filtered aqueous 0.02% thioflavin-S solution
(Chroma-Gesellschaft Schmid, Kongen, Germany) for 8 min.
Excess stain was removed by two brief rinses in 80% ethanol,
then two in distilled water, after which slides were finished in
aqueous mounting medium for florescence photomicrogra-
phy.
Ubiquitin, glial fibrillary acidic protein, and Ab immuno-
histochemistry. Prior to immunostaining, slides were depar-
affinized by oven heating followed by immersion in xylene.
After rehydration through graded alcohols into tap water,
endogenous peroxidase activity was quenched by incubation
with 3% hydrogen peroxide in methanol. Slides were micro-
waved for 5–7 min in water, cooled for 5 min, then washed in
TBS. Nonspecific staining was blocked for 1 h with 3%
normal goat serum and 0.1% Triton-X 100 in TBS. Slides
were then placed into primary antibody (rabbit anti-Ab
peptide polyclonal antibody, Zymed Laboratories, South San
Francisco, California, United States; rabbit anti-ubiquitin and
rabbit anti–glial fibrillary acidic protein (GFAP) polyclonal
antibodies, Dako, Carpinteria, California, United States)
diluted 1:500 in TBS with 2% normal goat serum and
incubated overnight at room temperature. After being
washed of excess primary antibody with several changes of
TBS, slides were incubated with either the Vectastain Elite
anti-rabbit secondary system (anti-Ab; Vector Laboratories,
Burlingame, California, United States) or peroxidase/anti-
peroxidase reagents (anti-ubitquitin and anti-GFAP; Stern-
berger Monoclonals, Lutherville, Maryland, United States)
according to the manufacturers’ directions. Antibody binding
was visualized with diaminobenzidene, and sections were
counterstained with hematoxylin.
Filter Trap Assay
An aliquot of each cortical homogenate used for Western
blotting above was partially solubilized by the addition of SDS
to a final concentration of 1%. Serial 1:2 dilutions were made
with 13 PBS/1% SDS, and 100 ll of each dilution was then
vacuum-filtered through a pre-wet 0.22-lm cellulose acetate
membrane (Schleicher and Schuell) [22]. Each well was
washed several times with PBS, after which blots were
incubated overnight with polyclonal anti-Ab antibody
(Zymed Laboratories) diluted 1:600 in a blocking solution of
13 TBS/5% nonfat dry milk powder. After washing the blots
three times for 10 min each in 13 TBS/0.1% Tween-20, the
membrane was incubated for 1 h with HRP-conjugated
protein A (Sigma) diluted 1:5,000 in blocking solution. The
membranes were again washed three times with 13TBS/0.1%
Tween-20, before antibody binding was detected with
enhanced chemiluminescence (PerkinElmer, Boston, Massa-
chusetts, United States). Digital images of each blot were
captured with a Molecular Imager FX gel documentation
system, and the intensity of Ab staining was quantified using
Quantity One image analysis software.
Ab ELISA
An aliquot of cortical homogenate generated for Western
analysis described above was subjected to a three-step
sequential extraction using PBS, 2% SDS, and 70% formic
acid (FA). At each step, the sample was sonicated in
appropriate buffer and centrifuged at 100,000g for 30 min
(1- to 1.5-mo samples) or 60 min (6- to 12-mo samples) at 4 8C
as previously described [23–25]. The supernatant was re-
moved for analysis, and the pellet was sonicated in the next
solution in sequence. The 2% SDS extracts were diluted in EC
buffer, and the FA extracts neutralized with 1M Tris-
phosphate buffer (pH 11) then diluted with EC buffer prior
to testing. Human Ab was measured in each fraction using
BAN50 for capture (epitope Ab1–16) and BA27 and BC05 for
detection (Ab40 and Ab42, respectively) (Takeda Chemical
Industries, Osaka, Japan). Total Ab (mouseþhuman; 1- to 1.5-
mo samples only) was measured in each fraction using BNT77
for capture (epitope Ab11–28) and BA27 and BC05 for
detection. All values were calculated as picomoles per gram
based on the initial weight of cortical tissue.
Activity Monitoring
Daily basal activity was studied in 28 CaMKIIa-tTA 3 tet-
APPswe/ind line 107 mice between 4 and 5 mo of age. Animals
were separated into individual cages immediately before the
start of each experiment (n¼3–6 per genotype untreated, 2–5
per genotype dox-reared). The cages were placed inside
activity-monitoring frames designed to count every time the
animal passed through one of three photobeams spanning the
width of the cage (San Diego Instruments, San Diego,
California, United States). Experiments were started midway
through the light phase of the day, and data were collected in
1-h bins for the following 48 h. Testing rooms were
maintained on the same 13:11 h day:night cycle as the main
animal housing areas and were closed to entry during the
experiment.
Statistical Analyses
Statistical analyses of protein expression, ELISA data, and
filter trap assays were performed by ANOVA with Tukey’s
honest significant difference post-hoc test applied to signifi-
cant main effects or interactions (Statistica 6.0, StatSoft,
Tulsa, Oklahoma, United States). In cases of positively skewed
data distribution, log10(xþ0.5) transformation was applied to
the raw data before submitting them to ANOVA.
Results
We used the tet-off transgene system to express a double
mutant version of chimeric mo/huAPP695 (swe/ind KM570,
571NL, and V617F) from a tetracycline-responsive promoter
[12,13]. Transgenic APP expression was activated by crossing
the APPswe/ind mice to animals producing tTA under control
of the CaMKIIa promoter [16]. After initial screening of
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founders, we identified four lines of tet-APPswe/ind mice that
produced very high levels of transgene product in offspring
coexpressing tTA (Figures 1 and S1). Compared to a standard
APP transgenic line used for previous amyloid studies by our
laboratory (line C3–3; [15,26,27]), we estimated that the four
controllable lines produce transgenic APP protein at 10- to
30-fold over endogenous levels (Figure S1). This estimate was
confirmed by direct comparison of APP levels in non-
transgenic and tet-off APP mice using an antibody that
recognizes both endogenous APP (and amyloid precursor-like
protein 2) and the transgenic protein (monoclonal antibody
22C11; Figure 1D).
Importantly, all four new lines of tet-off APP mice showed
nearly complete suppression of the transgene following dox
treatment (Figures 1 and S1). We focused on one of the four
lines, line 107, to examine in more detail the time depend-
ence and extent of transgene suppression following either
acute or chronic treatment with dox. Two dox-treated groups
were compared to two untreated groups: one group of mice
was born and raised on dox, a second group was treated with
dox for 2 wk starting at 1 mo of age (4 wk þ 2 wk dox); two
untreated groups kept on normal chow were harvested at
either 4 or 6 wk of age. Animals born and raised on dox
harbored no transgenic APP (Figure 1A). Following as little as
2 wk of dox treatment, transgenic APP expression was
reduced by more than 95% compared to pre-dox levels.
The residual expression remaining in acutely treated mice
represents less than 4% of the transgenic protein produced
in the absence of dox (Figure 1C), and likely results from
slight leakage at the level of transcription (data not shown).
Importantly, the total amount of APP (endogenous plus
transgenic) and related APLPs in both acute and chronically
treated animals was statistically indistinguishable from that in
nontransgenic mice (Figure 1D; statistical analyses for experi-
ments throughout the study are presented in the accompany-
ing figure legends).
To ensure that Ab production was suppressed in concert
with the dox-mediated inhibition of its precursor APPswe/
ind, we measured Ab40 and Ab42 levels by ELISA in forebrain
homogenates from young tet-off animals. At 1 mo of age, the
mice lacked visible amyloid aggregates that might act as an
intractable reservoir of peptide remaining in the brain after
the transgene had been suppressed. To further ensure we
could detect any such insoluble aggregates that might bias
our measure of changes in peptide synthesis, we performed a
sequential three-step extraction with PBS, 2% SDS, and 70%
Figure 1. Control of Transgenic APP Expression by Dox
(A) Western blotting for transgenic APP using the human-specific 6E10 antibody shows expression of full-length protein in forebrain tissue from young
predeposit double transgenic animals (line 107) and its suppression following dox treatment. Untreated animals show high levels of transgene
expression; protein levels drop dramatically in animals acutely treated with dox for 2 wk. A faint, but detectable band of full-length protein remains in
acutely treated animals that can be eliminated in mice born and raised on dox.
(B) Immunoblotting with the N-terminal antibody 22C11 to detect both transgenic and endogenous protein shows that dox treatment reduces APP/
APLP to levels found in nontransgenic mice.
(C) Measurement of signal intensity from the Western blot in (A) shows transgenic APP levels are decreased more than 95% by dox in both acutely and
chronically treated animals (97.2% for 4 wkþ2 wk dox, 98.0% for reared on dox versus 4 wk untreated; ANOVA effect of treatment group F4,15¼85.55, p
, 0.001). APP levels in 4 wkþ 2 wk dox, reared on dox, and nontransgenic (NTg) were not significantly different (p . 0.9, Tukey post-hoc test).
(D) Measurement of signal intensity from the Western blot in (B) shows total APP/APLP levels in dox-treated tTA/APP mice are significantly lower than in
4-wk-old untreated mice (ANOVA effect of treatment group F4,15¼ 84.41, p , 0.001) and indistinguishable from those of nontransgenic animals (p .
0.9, Tukey post-hoc test). *, p , 0.001 versus untreated 4-wk-old mice, Tukey post-hoc test applied to significant effect of group ANOVA.
DOI: 10.1371/journal.pmed.0020355.g001
PLoS Medicine | www.plosmedicine.org December 2005 | Volume 2 | Issue 12 | e3550005
Persistent Amyloid in Tet-Off APP Mice
FA that would separate peptides by solubility. We compared
the levels of human transgene-derived Ab40 and Ab42 in
untreated mice at 4 and 6 wk of age to animals that had either
been born and raised on dox or that had been left untreated
for 4 wk and then placed on dox chow for 2 wk prior to
harvest (the same groups described above for immunoblot
analysis of APPswe/ind levels, line 107). Consistent with the
reduction in full-length APPswe/ind synthesis shown by
immunoblot (see Figure 1), we found that transgene-derived
Ab levels were completely suppressed in animals born and
raised on dox, and were sharply reduced following acute (2
wk) antibiotic treatment. Compared to the levels in untreated
4-wk-old mice, PBS-soluble Ab42 dropped by 95.2% following
2 wk of dox treatment and by 99.2% with chronic treatment
(Figure 2A). Similarly, SDS-soluble Ab42 decreased by 75.2%
and 94.8% following 2-wk or lifelong dox treatment (Figure
2B). Only the FA fraction revealed a small dox-resistant pool
of peptide in acutely treated animals that we believe
represents stable predeposit aggregates that have already
accumulated by 4 wk of age when treatment was begun
(Figure 2C). Indeed, animals that were born and raised on dox
did not harbor this reservoir of treatment-resistant peptide,
with 96.3% less Ab42 than untreated 4-wk-old mice. Measure-
ment of total Ab in chronically treated mice, including
endogenous and transgene-derived peptide, demonstrated
that Ab levels in tet-off APP mice were reduced to the level of
Figure 2. Ab Levels Are Dramatically Reduced by Transgene Suppression
Cortical homogenates from young, predeposit tTA/APP mice used for
Western blot in Figure 1 (line 107) were fractionated by sequential multi-
step extraction with PBS, 2% SDS, and 70% FA followed by human-
specific Ab ELISA to measure transgene-derived peptide in each fraction.
Ab40 is shown in white, Ab42 in black.
(A) PBS-soluble Ab levels are substantially reduced by both acute and
chronic dox treatment (ANOVA, effect of treatment group F4,24¼ 137.10
and 386.01, p , 0.001, for Ab40 and Ab42, respectively). Ab levels in
treated animals are indistinguishable from nontransgenic (NTg) animals
(p . 0.3, Tukey post-hoc test).
(B) In the young animals tested here prior to the formation of visible
amyloid deposits, most Ab is extracted into the SDS fraction (84% and
76% of all transgene-derived Ab40 and Ab42, respectively). As in the PBS-
soluble fraction, Ab levels in the SDS fraction are significantly lowered by
dox treatment compared to untreated animals (ANOVA effect of group
F4,24 ¼ 197.57 and 163.48, p , 0.001, for Ab40 and Ab42, respectively).
Acutely treated animals retained a small (although significant) amount of
residual peptide (p , 0.001 compared to nontransgeinc, Tukey post-hoc
test), whereas Ab levels in mice born and raised on dox were reduced to
levels indistinguishable from nontransgenic (p . 0.8, Tukey post-hoc
test).
(C) The FA-soluble fraction already contains a small but significant pool
of aggregated Ab42 in untreated animals by 4 wk of age (p, 0.05 versus
nontransgenic; Tukey post-hoc test applied to significant effect of group
ANOVA F4,24¼ 17.11, p , 0.001). By 6 wk of age, the amount of Ab in the
FA fraction is increased significantly preceding the appearance of visible
deposits 2 wk later. The FA pool is the only peptide fraction not lowered
by acute dox treatment (4 wk untreated ¼ 4 wk þ 2 wk dox, p . 0.9,
Tukey post-hoc test), consistent with poor turnover of aggregated Ab
species.
(D) Measurements of total Ab, including both endogenous and trans-
gene-derived peptides, show that animals born and raised on dox harbor
Ab levels identical to nontransgenic animals (p . 0.9, Tukey post-hoc
test, effect of group ANOVA F4,24¼ 39.13 and 35.29, p , 0.001, for Ab40
and Ab42, respectively). Whereas chronic transgene suppression fully
prevents synthesis of both peptides, acute dox treatment fully
suppresses Ab40 levels (p . 0.8, Tukey post-hoc test), but leaves a
small amount of nonsuppressed Ab42. The residual Ab42 observed in
acutely treated young animals derives from uncleared aggregates
extracted in the SDS and FA fractions. *, p , 0.05; **, p , 0.005; ***, p
, 0.001 versus 4-wk-old untreated mice, Tukey post-hoc applied to
significant effect of group ANOVA.
DOI: 10.1371/journal.pmed.0020355.g002
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endogenous peptide found in nontransgenic animals (Figure
2D). Taken together with the immunoblotting data for full-
length APPswe/ind, the ELISA measurements indicate that
dox-mediated suppression of transgenic APPswe/ind synthesis
leads to parallel reduction of Ab levels.
The ELISA data also confirmed that incorporation of the
Swedish and Indiana mutations led to high levels of Ab42,
which we predicted would induce rapid plaque formation in
untreated animals. Histological characterization of double
transgenic (CaMKIIa-tTA 3 tet-APPswe/ind) mice revealed
early-onset amyloid formation in all four new lines. Amyloid
plaques were seen in mice as young as 8 wk of age (data not
shown). Plaques were limited to the forebrain, including the
cortex, hippocampus, olfactory bulb, and striatum, where the
CaMKIIa promoter is known to be most active [16,28] (Figure
S2). By 6 mo of age, amyloid burden became severe, covering
large areas of the cortex and hippocampus (Figure S3). No
lesions were seen in the cerebellum or brain stem even at late
ages, consistent with CaMKIIa-controlled transgene expres-
sion. Unlike what is thought to occur in the human disease,
the first visible plaques in the tet-off APP mice are fibrillar-
cored deposits. We have noted the same early appearance of
cored deposits in other lines of APP transgenic mice that
harbor the Swedish mutation [27]. Diffuse plaques were
apparent in 6-mo-old tTA/APP mice, and became relatively
abundant by 9 mo of age. At older ages (9–12 mo) amyloid
deposits were visible in the thalamus, which has also been
observed in mice expressing mutant APP via the Thy-1
promoter. The presence of amyloid pathology in this region
has been attributed to axonal transport of APP/Ab to the
terminals of cortical neurons in the thalamus [29]. Most
importantly, only double transgenic mice, expressing both
the tTA and APP transgenes, developed amyloid lesions.
Single transgenic mice up to 15 mo of age showed no sign of
pathology (Figure S3). Similarly, amyloid pathology can be
completely prevented in double transgenic animals born and
raised on dox. Animals from our highest expressing line (line
885) maintained on dox for up to 1 y harbored no amyloid
pathology (data not shown), indicating that residual leakage
of transgene expression in the presence of dox does not
provide sufficient Ab peptide to induce amyloid formation
even over long periods.
To mimic therapeutic intervention with inhibitors of Ab
production, we raised a group of 25 double transgenic mice
(CaMKIIa-tTA3APP line 107) on normal food until 6 mo of
age, when we knew amyloid formation was already well
underway in the brain. At 6 mo, half of the animals were
switched from normal chow to food containing dox at 200
mg/kg until they were sacrificed at 9 or 12 mo of age. The
remaining control animals were kept on standard chow
(untreated). In all, four cohorts were created: 6 mo untreated
(n¼7), 9 mo untreated (n¼5), 6 moþ3 mo treated (n¼8), and
6 mo þ 6 mo treated (n ¼ 5). Full suppression (.95%) of
transgenic APPswe/ind levels in the dox-treated animals was
confirmed by immunoblot (Figure 3). To ensure that the
transgene could be suppressed as rapidly in 6-mo-old mice
with fulminant pathology as it can in young, predeposit
animals, we treated an additional set of 6-mo-old animals
with dox for 1 wk prior to harvest. Importantly, both APPswe/
ind and APP–C-terminal fragment levels were fully sup-
pressed after only 1 wk of treatment, indicating that the in
vivo half-life of APPswe/ind and its processed C-terminal
fragments are relatively short (Figure 3D).
Tissue sections from each animal in the four treatment
groups were stained for amyloid pathology by Hirano silver,
Campbell-Switzer silver, thioflavin-S, and Ab immunohisto-
chemistry. As expected, the 6 mo untreated cohort displayed
moderate amyloid pathology, and the 9 mo untreated cohort
progressed to a severe amyloid burden. In contrast, the extent
of amyloid pathology in mice from the 6 moþ3 mo treated or
6 mo þ 6 mo treated cohorts closely resembled that of the 6
mo untreated cohort, despite the significant age difference
between the treated and untreated groups (Figures 4 and S3).
Well-formed plaques remained in the treated animals after 6
mo of transgene suppression, even though as much time was
given to clear the lesions as they had taken to form. Moreover,
both types of amyloid, diffuse and fibrillar, remained intact
throughout treatment. Using the Campbell-Switzer silver
stain to distinguish different forms of amyloid, we found
diffuse plaques were as persistent as cored deposits (Figure
S4). It was nevertheless clear that dox-induced suppression of
transgenic APP had completely halted the progression of
pathology.
To confirm that the arrest of plaques without any sign of
clearance was not unique to the line 107 mice, we repeated
the dox-suppression experiment in a second line of tet-off
APP mice (CaMKIIa-tTA 3 tet-APPswe/ind line 18; n ¼ 22).
Again, long-term dox treatment was begun at 6 mo of age,
and mice were harvested after 3 mo of transgene suppression
(6 mo untreated, n ¼ 8; 9 mo untreated, n ¼ 6; 6 mo þ 3 mo
treated, n ¼ 8). Immunoblotting for APP confirmed full
transgene suppression in the treated animals (Figure S5). As
in the line 107 mice described above, amyloid burden
worsened substantially in the untreated mice between 6 and
9 mo of age. Suppression of transgene expression abruptly
arrested progression of pathology (Figure S6), but again
without any sign of reduction. Both silver- and thioflavin-S-
positive plaques could still be found in each of the dox-
treated animals.
We biochemically measured the amount of aggregated Ab
in the brains of our mice before and after transgene
suppression using filter trap analysis of cortical tissue from
each animal. In this assay, serial dilutions of protein
homogenate are passed through a cellulose acetate filter;
particles larger than the pore size of the filter become
trapped in the membrane and are revealed by immunoblot-
ting [22]. Consistent with our visual analysis of the histo-
logical sections, line 107 tTA/APP mice treated with dox for 3
or 6 mo had the same amount of aggregated Ab as when they
started treatment at 6 mo of age (Figure 4A and 4B). In
contrast, untreated 9-mo-old mice had almost twice as much
aggregated Ab as either of the treated groups. Filter trap
analysis of line 18 tTA/APP mice yielded similar results: the
increase in aggregated Ab observed in untreated animals
between 6 and 9 mo of age was completely arrested by
transgene suppression (Figure S5C and S5D).
We next used ELISA to measure total Ab in the brains of
each group to determine whether any change in the amount
or solubility of peptide occurred while APPswe/ind expres-
sion was suppressed. Cortical homogenates were sequentially
extracted to separate peptide into PBS-, SDS-, and FA-soluble
fractions, then transgene-derived Ab40 and Ab42 were
measured by human-specific ELISA [23]. In all animals
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harboring amyloid deposits, we found that the vast majority
of Ab (.99%) was extracted into the SDS and FA fractions
(Figure 5A and 5B). Consistent with the filter trap results
presented above, there were no significant differences in
SDS- or FA-soluble Ab between the 6 mo untreated cohort
and either the 6 mo þ 3 mo treated or 6 mo þ 6 mo treated
cohorts. However, brains of both 6 moþ 3 mo and 6 moþ 6
mo treated cohorts contained roughly twice as much PBS-
soluble Ab40 as untreated 6-mo-old mice (Figure 5C). Levels
of Ab42 showed a similar trend, but did not reach statistical
significance. In fact, levels of PBS-soluble Ab40 and Ab42 in
the 6 moþ 3 mo and 6 moþ 6 mo treated cohorts were most
similar to that of the 9 mo untreated cohort, suggesting that
age, as opposed to synthetic rate (which would be negligible
in the treated animals), may determine the fraction of PBS-
soluble Ab in these animals.
We also assessed neuritic and glial pathology surrounding
the plaques to determine whether there were any changes in
nearby tissue following long-term transgene suppression.
Both Hirano silver stain and ubiquitin immunostaining
showed neuritic pathology in all treatment groups (Figure
6). Similarly, activated astrocytes immunostained for GFAP
were found near plaques in all animals (Figure 6). Neuritic
and glial pathology were more severe in the older untreated
mice. In contrast, transgene suppression prevented the
growth of individual deposits apparent in untreated mice,
and limited the surrounding pathology to what was already
present when treatment began.
An obvious question we sought to address was whether the
deposition of Ab diminished cognitive ability in untreated
mice, and what might happen to cognition when the process
was interrupted. Unfortunately, efforts to characterize
Figure 3. Robust Transgene Suppression in Older Mice with Preexisting Amyloid Pathology
(A) Cortical homogenates from 6- to 12-mo-old animals used for pathology studies described below (line 107) were immunoblotted with human-
specific antibody 6E10 to examine transgene suppression following 3 or 6 mo of dox treatment. The blot was co-immunostained for endogenous
superoxide dismutase 1 (SOD1) as a control for loading.
(B) Quantitation of signal intensity from the Western blot shown in (A). Transgenic APP levels are significantly suppressed following 3 or 6 mo of dox
treatment (96.9% and 97.6%, respectively). *, p , 0.001 compared to 6-mo-old untreated animals, Tukey post-hoc test applied to significant effect of
group ANOVA F3,12 ¼ 107.22, p , 0.001. These data demonstrate that strong transgene suppression is attained both before and after the onset of
amyloid pathology (see Figure 1 for predeposit experiments).
(C) Experimental design. To examine the effects of chronic Ab suppression on amyloid pathology after the onset of deposition, we compared untreated
controls harvested at 6 and 9 mo of age to animals placed on dox at 6 mo of age and harvested after 3 or 6 mo of treatment.
(D) Dox treatment leads to rapid transgene suppression even in 6-mo-old tTA/APP mice. Immunostaining with 6E10 shows APPswe/ind levels are
dramatically reduced in 6-mo-old mice treated for 1 wk with dox (upper panel). A separate blot was immunostained for APP C-terminal fragments with
CT15 antibody to show that the precursors to Ab cleavage are decreased in parallel with the full-length protein (middle panel). Costaining for
superoxide dismutase 1 was used as an internal control for loading (lower panel, taken from bottom half of 6E10 blot).
DOI: 10.1371/journal.pmed.0020355.g003
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cognitive behavior were compromised by severe hyperactivity
in untreated double transgenic mice. The tTA/APP animals
were often seen running in circles around the perimeter of
their cages, and a similar swimming pattern was noted when
the mice were tested in the Morris water maze. In the radial
water maze, repetitive swim patterns were noted with no
evidence of choice-motivated actions. Other studies have
dealt with similar problems by excluding animals that do not
show adequate attention to the task, retaining only those
mice that meet certain performance criteria [30]. In our case,
the penetrance of hyperactivity was close to 100%, leaving us
with no testable animals. This phenotype has not affected
previous lines of APPswe mice we have produced, such as
lines E1–2 or C3–3, that express lower levels of transgenic
protein. Indeed, in past studies where hyperactivity was not a
factor, we established a clear relationship between amyloid
load and cognitive ability [31]. However, in the current study,
we feel that although the poor performance of the tTA/APP
mice in the maze tests could technically be scored as cognitive
impairment, the animals’ severe hyperactivity made inter-
pretation of the cognitive tasks impossible.
In order to understand the nature and extent of hyper-
activity in the tTA/APP mice, we quantified daily activity
levels in double transgenic animals along with their single
Figure 4. Suppression of Transgenic APP Arrests Progression of Amyloid Pathology
(A) Aggregated Ab was quantified in cortical tissue from dox-treated and control tTA/APP mice (line 107) using a filter trap assay. Serial dilutions of
protein homogenate were passed through a cellulose acetate filter; protein aggregates larger than the pore size were trapped and immunostained for
Ab.
(B) Quantitation of signal intensity in the linear range of each filter trap dilution series (arrow in [A]) was used to compare aggregate load across
treatment groups. Aggregated Ab increased significantly between 6 and 9 mo of age in untreated mice (significant effect of group ANOVA F3,18¼ 7.85,
p , 0.002). This progression of pathology was completely prevented by transgene suppression. The amount of aggregated Ab was identical in
untreated mice at 6 mo of age to that in 9- or 12-mo-old animals treated with dox ( p . 0.9, Tukey post-hoc test). Single transgenic tTA samples were
included as negative controls and showed no signal above background. *, p , 0.01; **, p , 0.005 versus 9-mo-old untreated mice, Tukey post-hoc test;
***, p , 0.001 versus 9-mo-old untreated mice, Student’s t-test.
(C) Amyloid pathology in the hippocampus of representative mice from each treatment group: Hirano silver stain (top row), thioflavin-S (middle row),
and Ab immunohistochemistry (bottom row). Amyloid burden increases dramatically between 6 and 9 mo of age in untreated animals, but remains
stable in transgene-suppressed mice over the same period (6 moþ 3 mo dox and 6 moþ 6 mo dox). Single transgenic animals (tTA only shown here)
show no sign of amyloid pathology at any age tested.
DOI: 10.1371/journal.pmed.0020355.g004
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transgenic and nontransgenic siblings using four-beam
frames designed to monitor ambulation within an enclosed
cage. As shown in Figure 7, the double transgenic mice were
up to 10-fold more active during the dark phase of the day–
night cycle than any of the control groups. Activity levels
appeared to follow a relatively normal diurnal cycle,
decreasing substantially during the daylight hours. However,
even during the light phase, the tTA/APP mice remained
many-fold more active than normal controls. This behavior
was partially, but not consistently, reversed by 1 mo of
transgene suppression beginning at 4–5 mo of age (data not
shown). In contrast, hyperactivity was completely abolished
by rearing tTA/APP mice on dox. Animals born and raised on
dox showed activity levels similar to the untreated controls
(Figure 7C). Intriguingly, all of the dox-reared animals, both
transgenic and wild-type, showed altered circadian rhythms
with far less distinction between their day- and nighttime
activity levels.
Discussion
We present a new mouse model for AD that was designed
to test the consequences of inhibiting Ab production after
the onset of amyloid pathology. New lines of transgenic mice
were developed for this study that express high levels of
APPswe/ind under the control of a tetracycline-responsive
promoter. We demonstrate that treatment with dox sup-
presses steady-state levels of both APPswe/ind and its C-
terminal fragments, indicating that the mutant proteins have
a relatively short half-life in vivo. Transgenic expression of
APPswe/ind and consequent overproduction of Ab42 cause
early-onset amyloid deposition in untreated mice, in which
deposits appear as early as 2 mo of age. Amyloid burden
worsens significantly with age, and by 9 mo, the hippocampus
and cortex of untreated mice are largely filled with
aggregated peptide. We find that suppression of transgenic
APP by more than 95% abruptly halts the progression of
amyloid pathology. Importantly, this outcome occurs in
animals already harboring considerable amyloid pathology,
a situation similar to what might be expected in patients to be
treated with secretase inhibitors. Somewhat unexpectedly, we
observe no appreciable clearance of deposited amyloid even
following periods of transgene suppression equal to the time
taken for plaques to form. This latter finding indicates that
compared to other disease-associated protein aggregates such
as mutant huntingtin, which clear in less than 3 mo [32], the
disaggregation of extracellular amyloid is relatively slow.
Notably, pharmaceutical c-secretase inhibitors published
to date show less strict regulation of Ab production following
chronic administration than we have attained here. Two
independent compounds tested in Tg2576 [33] and TgCRND8
Figure 5. Ab ELISA Confirms Arrest of Progression without Clearance of
Peptide in Mice with Preexisting Aggregates
Ab levels in untreated 6- and 9-mo-old tTA/APP line 107 mice (shown
in Figure 4) were compared to those in 9- and 12-mo-old animals
treated with dox from the age of 6 mo. Single transgenic APP samples
were included as negative controls. Cortical homogenates were
fractionated by sequential multi-step extraction with PBS, 2% SDS,
and 70% FA followed by human-specific Ab ELISA to measure
transgene-derived peptide in each fraction. Ab40 is shown in white,
Ab42 in black.
(A and B) Most Ab in the brains of plaque-bearing mice is extracted into
the FA and SDS fractions. Consistent with amyloid burden (Figures 4 and
S3), SDS- and FA-extracted Ab levels in untreated 9-mo-old mice were
significantly higher than in untreated 6-mo-old mice (Tukey post-hoc test
applied to significant effect of group ANOVA for SDS and FA fractions
F3,18 ¼ 4.72–12.92, p , 0.02). In contrast, 3 or 6 mo of transgene
suppression held Ab at levels equivalent to those harbored when
treatment was started (p . 0.2 compared to 6 mo untreated mice, Tukey
post-hoc test). *, p , 0.05; **, p , 0.005; ***, p , 0.001 versus 9-mo-old
untreated mice, Tukey post-hoc test. Significance for APP versus 9-mo-
old untreated mice is based on Student’s t-test.
(C) The PBS fraction represents less than 0.1% of total Ab (note the
change in y-axis from [A] and [B]), but only here do Ab levels in the dox-
treated mice differ from those in younger untreated mice. Although both
peptides appear elevated in the treated groups compared to the
untreated 6-mo-old mice, only Ab40 reaches statistical significance (p ,
0.05, Tukey post-hoc test applied to significant effect of group ANOVA
for Ab40 F3,18¼ 4.60, p , 0.02). A similar trend was seen for Ab42, where
ANOVA yielded a significant effect of group for PBS-soluble Ab42 (F3,18¼
3.75, p , 0.03), however this was due only to differences between the
untreated 6- and 9-mo-old groups. , p, 0.05 versus 6-mo-old untreated
mice, Tukey post-hoc test; , p , 0.001 versus 6-mo-old untreated
mice, Student’s t-test.
DOI: 10.1371/journal.pmed.0020355.g005
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[34] transgenic mice show no more than 85% suppression of
Ab40 levels, and where measured, even less suppression of
Ab42 (approximately 60%) [35,36]. Thus, even after account-
ing for the much higher APP expression levels in our mice
than in the Tg2576 and TgCRND8 lines, we have achieved
better absolute suppression of Ab production with the tet-off
system than is currently possible with published c-secretase
inhibitors. Since even the most advanced future pharmaceut-
ical agents are unlikely to attain more complete control of Ab
production than achieved here, this system provides a salient
test of therapeutic intervention with Ab-lowering com-
pounds.
Although the progression of amyloid deposition was
sharply arrested by this approach, we found that a substantial
amyloid burden remained even after long periods of trans-
gene suppression. We examined a small number of animals
after 12 mo of dox treatment (beginning at 6 mo of age), and
found that amyloid deposits were still relatively abundant.
Longer-term treatments are now in progress. At the latest
treatment interval analyzed by ELISA, animals administered
dox for 6 mo showed elevated levels of PBS-soluble Ab (see
Figure 5) that could be interpreted as an indication that the
plaques are slowly releasing peptide (or oligomeric Ab) into
the soluble pool and might eventually dissolve. Whether
inhibiting Ab production longer than 6 (or 12) mo may
ultimately result in clearance of amyloid is under inves-
tigation; unfortunately, the life span of the model eventually
limits this experiment. Therapeutics used in humans will have
considerably more time to act than is possible within the life
span of rodent models. Long-term treatments would certainly
be possible and could be a key to effective therapy. Overall,
however, we interpret our findings as evidence that AD
therapies that significantly lower the production of Ab (by
either inhibiting secretase activity or inhibiting APP expres-
sion) may not quickly reverse preexisting pathology, but
should effectively halt further deposition of amyloid.
In interpreting our study, it should be remembered that the
earliest plaques to appear in these mice, like other APP
transgenics harboring the Swedish mutation [27], are pre-
dominantly fibrillar deposits, which may be less tractable than
the diffuse aggregates thought to come first in the course of
the human disease. However, our data suggest that once
diffuse deposits are formed in these mice, they are no more
easily cleared in our system than cored plaques (see Figure
S4). An additional consideration we recognize is that a small
amount of transgene expression continues in the presence of
dox and that endogenous mouse Ab continues to be
produced. It is possible that the combined low levels of
endogenous mouse Ab and nonsuppressed human peptide
are sufficient to maintain existing deposits. However, these
low levels of peptide are not sufficient to induce new amyloid
formation, as CaMKIIa-tTA 3 tetAPPswe/ind mice raised on
dox for up to a year do not develop amyloid lesions (data not
shown). It is also clear that in this genetic system, we have
raised the production of Ab to levels not found in humans to
accelerate pathology into an experimentally feasible time
Figure 6. Neuritic and Glial Pathology Are Unchanged following Transgene Suppression
Dystrophic neurites and activated astrocytes surround most compact plaques in tet-off APP mice (line 107). Dark-stained, ubiquitin-filled neurites and
reactive astrocytes form a halo around cored, fibrillar deposits by 6 mo of age that worsens with time in untreated mice. Both plaque-associated
pathologies are arrested, although not reversed, by transgene suppression. Hirano silver stain (top row); GFAP immunohistochemistry (middle row);
ubiquitin immunohistochemistry (bottom row).
DOI: 10.1371/journal.pmed.0020355.g006
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frame. This system allowed us to create an approximately 20-
fold differential between APP/Ab synthetic rates before and
after treatment, yet the in vivo equilibrium between
aggregated and disaggregated states of Ab still favored the
maintenance of amyloid deposits. In our opinion, it seems
unlikely that amyloid deposits in human brain would be
inherently any less stable than those formed in mouse brain.
However, the human brain may harbor clearance mechanisms
not shared by mice that would allow more efficient removal
of preexisting amyloid.
One potential mechanism by which amyloid may be more
efficiently removed in the human disease than in the mouse
models is through microglial phagocytosis. Resident micro-
glia in transgenic mouse models localize to tissue surrounding
plaques but show little evidence of amyloid engulfment [37–
40]. In contrast, microglia surrounding amyloid plaques in
human brain show a much higher state of activation with
greater expression of complement receptor [40]. Thus, the
role of microglia in amyloid metabolism is minor in trans-
genic models compared to the human condition. Somewhat
paradoxically, several studies further demonstrate that treat-
ment with anti-inflammatory drugs to reduce microglial
activation actually lowers amyloid load in APP transgenic
mice, suggesting a role for mouse microglia in the formation
and maintenance of amyloid aggregates [41–43]. However,
this outcome may be alternatively explained by direct effects
of many anti-inflammatory drugs on c-secretase cleavage [44–
47]. Nonetheless, the role of microglia in both the human
condition and the mouse models is poorly understood, and
differences in microglial reactivity between the two could
lead to significantly faster amyloid clearance in the brains of
patients with AD than we observe in the tet-off APP mice.
Given the relatively minor role played by microglia in other
mouse models of amyloidosis, we think it unlikely that these
cells have influenced the rate of amyloid clearance in the tet-
off APP mice. Even so, we considered the possibility that
chronic dox treatment may have altered the activation state
of microglia in our treated mice. Dox is structurally similar to
minocycline, a reported anti-inflammatory drug and inhib-
itor of microglial activation [48]. However, if dox does have
anti-inflammatory activity, then, based on previous studies
with other anti-inflammatories, we would have expected to
find less amyloid in the dox-treated animals. Clearly, that was
not the case. While it is possible that dox acts in some other
Figure 7. Transgene Suppression Attenuates Hyperactivity in tTA/APP Mice
(A) A 48-h measure of ambulation records extreme hyperactivity in untreated double transgenic mice compared to single transgenic and nontransgenic
controls (line 107). This phenotype is completely eliminated by rearing the double transgenic mice on dox.
(B) The same data shown in (A) are replotted to magnify data from untreated control and dox-treated groups.
(C and D) Activity levels in the combined control groups of (A) and (B) are here separated by genotype. None of the single transgenic or nontransgenic
control groups display the hyperactivity present in untreated tTA/APP animals. Again, note the y-axes have been enlarged for detail compared to (A).
DOI: 10.1371/journal.pmed.0020355.g007
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way to slow amyloid clearance, data from multiple studies
demonstrate that microglial responses are normally weak in
the mouse AD models [37–40], and thus it is doubtful that
dox-mediated microglial inhibition affected the outcome of
our study.
The persistence and stability of amyloid deposits in our
system is unexpected given the speed with which Ab
aggregates are cleared in other mouse models of therapeutic
intervention. Anti-Ab antibodies injected directly into the
brain have been shown to eliminate amyloid deposits in as
little as 1 wk after treatment [49–51]. Peripheral antibody
injection decreases amyloid load more broadly, and although
it does not appear to act as quickly as local injection, can
significantly reduce amyloid load within 2 mo of initial
treatment [52,53]. More recently, an alternative approach has
shown that lentiviral transfer of neprilysin can also reduce
the number of aggregates in the area of the injection site [54].
Careful study of the mechanism behind several of the
antibody-mediated therapies has suggested that activated
microglia play an important role in the removal of fibrillar
plaques after immunization [50,52,55]. However, it has been
noted that deletion of the Fc receptor (the primary receptor
for microglial opsinization of antibody–antigen complexes)
in APP transgenic mouse models has no impact on the
effectiveness of antibody-mediated therapy [56,57]. It is,
nevertheless, possible that lack of microglia activation is the
major difference between the slow clearance described here,
where no perturbation of the immune system is expected, and
the rapid clearance described in studies involving antibody or
viral injection. In isolation, mild activation of microglia by
injection damage or opsinization may not be adequate to
induce substantial phagocytosis, but when combined with an
Ab-lowering agent, such as neprilysin or Ab-targeted anti-
bodies, the two may work in concert to clear peptide deposits.
Consistent with this hypothesis, strong activation of microglia
through transgenic expression of TGFb [58] or central
injection of lipopolysaccharide [59,60] can by itself substan-
tially reduce plaque burden in APP transgenic mice. But in
the case of acute antibody- and/or injury-mediated activation,
once the inflammation has passed, and the antibody and
bound peptide have been cleared and degraded, the remain-
ing Ab quickly reaggregates and amyloid pathology is
reestablished [49]. This finding reinforces the notion that
without continued stimulation, microglia in mouse models do
not maintain the same level of sustained activation that may
occur in humans.
SantaCruz et al. recently published a study of mice that
express P301L human tau via a similar vector system [61]. As
in our tet-off APP mice, SantaCruz et al. found that tau
neurofibrillary tangles, like amyloid plaques, are not cleared
efficiently following transgene suppression. The lack of
clearance in both models of AD pathology comes as a stark
contrast to the rapid removal of protein aggregates found in
similar tet-off mouse models of Huntington [32] and prion
disease [62]. In these cases, disrupting the input of new
monomer to the system via dox-mediated transgene suppres-
sion led to relatively rapid clearance of protein aggregates. By
contrast, our study and that of SantaCruz et al. suggest that
protein aggregates in AD may be more tenacious than in
other neurodegenerative disorders. Perhaps once aggregated,
Ab and tau are either inherently more stable than other
protein aggregates or more resistant to intra- and extrac-
ellular clearance mechanisms.
One question we were not able to address in this study is
whether abrogating synthesis of new Ab halts the progression
of cognitive decline. Studies from the tet-off tau mice suggest
that protein clearance may in fact not be required for
cognitive improvement following transgene suppression [61].
At present, because of unexpected noncognitive behavioral
abnormalities, it is not clear whether the tet-off APP mice can
be used to address the same question in the context of
amyloid pathology. Both lines of tTA/APP mice we studied
here display extreme hyperactivity visible as cage circling and
quantified by activity monitoring (see Figure 7). Many of the
double transgenic mice showed similar circular patterns of
swimming near the edge of the tank when tested in the Morris
water maze. Expression of this phenotype makes standard
tests of learning and memory uninterpretable. Hyperactivity
nonspecifically inhibits choice-driven changes in movement,
the key element behind all cognitive behavioral paradigms.
We are currently working to determine whether hyperactivity
correlates with expression of the APPswe/ind holoprotein or
its proteolytic derivatives. Preliminary studies suggest that
hyperactivity does not appear quickly when dox-reared mice
are shifted to nonmedicated diets (J. L. J., unpublished data).
These data may indicate that the neuroactive culprit is not
immediately present after transgenic APP synthesis is
initiated, but requires additional time to develop. Alterna-
tively, hyperactivity may be caused by neuronal alterations
due to transgene expression during early postnatal develop-
ment. Further experiments are needed to distinguish between
these possibilities.
In summary, we demonstrate that abrogating Ab produc-
tion halts the progression of pathologic changes in a
transgenic mouse model of Alzheimer-type amyloidosis.
However, despite dramatic reductions in Ab synthesis,
neuritic plaques are stable structures in vivo that do not
quickly disaggregate. It is possible that a combination of
therapies to limit Ab production, increase Ab degradation,
and enhance phagocytosis of deposited amyloid may be
required to reverse damage associated with AD. However, if
started early enough in the course of disease, secretase
inhibitors alone could provide substantial benefit in slowing
pathogenic processes linked to amyloid deposition. Even at
later stages in the disease, the presence of substantial
microglial activation in human AD [40] suggests that simply
slowing the formation of new amyloid deposits may allow
ongoing phagocytosis to diminish preexisting lesions. How-
ever, the development of safe and effective secretase
inhibitors will ultimately be required to determine whether
the human brain has the capacity to repair amyloid-
associated damage of AD once the progression of pathology
is arrested.
Supporting Information
Figure S1. Transgenic APP Expression and Suppression by Dox in the
Four New Tet-Off APP Lines
Western blotting with human-specific antibody 6E10 reveals trans-
gene-derived full-length APP in cortical homogenates from untreated
animals (left lanes of each panel). The new lines produce exception-
ally high levels of transgene expression; an equal amount of brain
homogenate from a standard transgenic APP line is shown for
comparison (extreme left lane, Standard Tg line C3–3; [15,63]). After
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1 mo of dox treatment, transgenic protein in all four new tet-off APP
lines is reduced to residual levels (þ dox; right lanes of each panel).
DOI: 10.1371/journal.pmed.0020355.sg001 (474 KB TIF).
Figure S2. Transgenic APP mRNA Is Brain-Specific
A slot blot of mRNA harvested from various tissues in three of the
four new tet-off APP lines and a nontransgenic control was used to
examine transgenic mRNA expression. Hybridization is seen only in
the brain; no signal above background is seen in any other tissue.
DOI: 10.1371/journal.pmed.0020355.sg002 (781 KB PSD).
Figure S3. Amyloid Pathology in the Cortex Reiterates That in the
Hippocampus
Amyloid histology was performed on sections from line 107 double
transgenic mice by Hirano silver stain (top row), thioflavin-S (middle
row), and Ab immunohistochemistry (bottom row) to examine the
persistence of pathology following transgene suppression. As in the
hippocampus (see Figure 4 and text), the progression of amyloid
pathology in the cortex worsens substantially between 6 and 9 mo of
age in untreated mice. This progression is completely prevented by
suppression of the transgene with dox. For comparison, normal
neurohistology is shown in an age-matched single transgenic (tTA
only) animal. No amyloid pathology has been detected in either APP
or tTA single transgenic animals up to 15 mo of age.
DOI: 10.1371/journal.pmed.0020355.sg003 (4.8 MB PSD).
Figure S4. Diffuse Deposits Do Not Disperse During Ab Suppression
Campbell–Switzer silver stain was used to differentiate cored (brown)
from diffuse (black) deposits in line 107 tTA/APP mice. This stain
demonstrates that both types of deposit persist throughout long
periods of transgene suppression. The lower panels, showing low-
power images (103) of frontal cortex from each condition, reveal
little change in the extent of diffuse amyloid following up to 6 mo of
Ab suppression. High-power images (403) in the upper panels show
that the diffuse halo surrounding individual cored deposits remains
relatively unchanged in treated mice. Untreated tTA single trans-
genic animals are shown as a negative control. Protocol for the
Campbell-Switzer Alzheimer’s Method was kindly shared by Robert
Switzer, III (NeuroScience Associates, Knoxville, Tennessee, United
States), and can be downloaded at http://www.nsalabs.com/
Documents/publications/campbell-switzer_protocol.htm [64,65].
DOI: 10.1371/journal.pmed.0020355.sg004 (923 KB JPG).
Figure S5. Chronic Transgene Suppression and Arrest of Ab
Aggregate Formation in an Independent Line of Tet-Off APP Mice
(CaMKIIa-tTA3 tet-APPswe/ind Line 18)
(A) The experiment presented in the text for line 107 tet-off APP was
repeated with a second tet-off APP line (line 18) to control for
integration site artifacts. Cortical homogenates from untreated
control and dox-treated double transgenic mice were immunoblotted
for full-length APP with the human-specific antibody 6E10 to confirm
transgene suppression at the time of harvest. Immunostaining for
endogenous superoxide dismutase (SOD1) was included as a loading
control.
(B) Quantitation of signal intensity from the Western blot in (A)
shows transgenic APP levels in line 18 are suppressed by more than
98% following 3 mo of dox treatment (significant effect of group
ANOVA F2,8¼ 1559.7, p , 0.001). This level of suppression was equal
to or better than that attained in line 107 (see Figure 3B).
(C) Serial dilution filter trap assay was used to quantify aggregated Ab
in cortical homogenates.
(D) Quantitation of signal intensity in the linear range of the dilution
series shown in (C). Consistent with the amyloid histology shown in
Figure S5, aggregate formation was significantly increased between 6
and 9 mo of age in untreated mice (significant effect of group ANOVA
F2,18¼12.14, p, 0.001). Aggregate formation was completely arrested
by transgene suppression, and is identical in 9-mo-old mice treated
with dox for 3 mo as in untreated animals harvested when treatment
began (p. 0.5, Tukey post-hoc test). *, p, 0.05; **, p, 0.005; ***, p,
0.001 versus 9-mo-old untreated mice, Tukey post-hoc test.
DOI: 10.1371/journal.pmed.0020355.sg005 (962 KB TIF).
Figure S6. Arrest of Amyloid Progression by Chronic Transgene
Suppression in Line 18 Tet-Off APP Mice
Amyloid histology in cortical (first and third rows) and hippocampal
(second and fourth rows) sections from untreated tTA/APP mice
shows a dramatic progression of pathology between 6 and 9 mo of
age. Suppression of transgenic APP expression arrests this progres-
sion, although without any sign of plaque clearance (6 mo þ 3 mo
dox). Hirano silver stain (top panels); thioflavin-S (bottom panels).
DOI: 10.1371/journal.pmed.0020355.sg006 (5.8 MB PSD).
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Patient Summary
Background Patients with Alzheimer disease (AD) have elevated levels
of a small protein called amyloid-b peptide that sticks together to form
what are known as amyloid plaques in their brains. This peptide is
normally made at low levels in healthy individuals, and is made when a
larger protein called amyloid precursor protein (APP) is cut down in size.
New treatments are now being developed that will decrease the amount
of Ab produced from APP. However, it is not clear whether lowering the
production of Ab will allow the brain to heal itself by clearing the
amyloid plaques. The answer to this question may be important for
deciding when Ab-lowering drugs should be started, and may also
determine how effective they are in reversing the mental symptoms of
AD.
What Did the Researchers Do and Find? Because new drugs designed
to lower Ab levels are still in development, they are not available for
testing in animal models of the disease. Instead, basic questions about
the effectiveness of this type of treatment must be answered using
systems that mimic how the drugs work. To do this, the authors created
mice that produce too much APP and that develop the same amyloid
lesions as do human patients with AD. Unlike normal mice, these mice
also carried a ‘‘switch’’ gene that allowed the researchers to turn off APP
by feeding the mice special food. Turning off APP in these mice had the
same effect as treating them with Ab-lowering drugs, and so the
researchers were able to ask what happened to the amyloid plaques
after Ab production was shut down. They showed that lowering Ab
production prevents the amyloid lesions from getting worse as the
disease progresses. This means that treatment with Ab-lowering drugs
may be able to stop the disease from filling the brain with plaques.
However, the researchers also found that the amyloid lesions that had
formed before treatment was started remained intact throughout the
experiment.
What Do These Findings Mean? These results indicate that treatments
designed to lower the production of Ab may be an important part of
future AD treatment, as this approach seems to prevents additional
amyloid plaques from forming in the mouse brain. However, by itself,
this strategy may not be able to rid the brain of plaques that have
already formed in the brain before treatment is started. The findings
suggest that early treatment may be important for this approach to
succeed.
Where Can I Get More Information Online? MedlinePlus has several
Web pages of information on Alzheimer disease:
http://www.nlm.nih.gov/medlineplus/alzheimersdisease.html
The ADEAR Center of the US Government’s National Institute on Aging
also has information on Alzheimer disease:
http://www.alzheimers.org/
The Alzheimer’s Association Web site contains information on both
caregiving and research:
http://www.alz.org
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